{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T17:10:09.840449+00:00","company":{"ticker":"BVS","cik":1665988,"company_name":"Bioventus Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"53b28c2199fa52b02fd20d72dff4af81056644e2","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2026-06-04T11:54:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"45,672","votes_against":"5,021","votes_for":"75,228,481","votes_withheld":null}]},"claim":"Bioventus Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.","evidence_excerpt":"The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001665988-26-000035","anchor_url":"https://secwatch.observer/filing/0001665988-26-000035#claim-53b28c2199fa52b02fd20d72dff4af81056644e2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000035/0001665988-26-000035-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1b2b0369e0d046348c97cc511befab6d9fee084a","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2026-06-04T11:54:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"6,744,219","subject":"William A. Hawkins","votes_abstain":null,"votes_against":null,"votes_for":"67,405,961","votes_withheld":"1,128,994"},{"broker_non_votes":"6,744,219","subject":"John A. Bartholdson","votes_abstain":null,"votes_against":null,"votes_for":"68,365,980","votes_withheld":"168,975"},{"broker_non_votes":"6,744,219","subject":"Patrick J. Beyer","votes_abstain":null,"votes_against":null,"votes_for":"68,062,114","votes_withheld":"472,841"},{"broker_non_votes":"6,744,219","subject":"Robert E. Claypoole","votes_abstain":null,"votes_against":null,"votes_for":"68,360,467","votes_withheld":"174,488"},{"broker_non_votes":"6,744,219","subject":"Philip G. Cowdy","votes_abstain":null,"votes_against":null,"votes_for":"67,748,512","votes_withheld":"786,443"},{"broker_non_votes":"6,744,219","subject":"Ajay Dhankhar","votes_abstain":null,"votes_against":null,"votes_for":"68,459,149","votes_withheld":"75,806"},{"broker_non_votes":"6,744,219","subject":"Mary Kay Ladone","votes_abstain":null,"votes_against":null,"votes_for":"67,160,936","votes_withheld":"1,374,019"},{"broker_non_votes":"6,744,219","subject":"Michelle McMurry-Heath","votes_abstain":null,"votes_against":null,"votes_for":"68,073,685","votes_withheld":"461,270"},{"broker_non_votes":"6,744,219","subject":"Guido J. Neels","votes_abstain":null,"votes_against":null,"votes_for":"68,049,659","votes_withheld":"485,296"},{"broker_non_votes":"6,744,219","subject":"Guy P. Nohra","votes_abstain":null,"votes_against":null,"votes_for":"67,767,651","votes_withheld":"767,304"},{"broker_non_votes":"6,744,219","subject":"Susan M. Stalnecker","votes_abstain":null,"votes_against":null,"votes_for":"68,060,987","votes_withheld":"473,968"},{"broker_non_votes":"6,744,219","subject":"Martin P. Sutter","votes_abstain":null,"votes_against":null,"votes_for":"61,710,650","votes_withheld":"6,824,305"}]},"claim":"Bioventus Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.","evidence_excerpt":"The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below. At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company’s Board of Directors until the 2027 annual meeting of stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s death, resignation or removal, based on the following votes: Nominee For Withheld Broker Non-Votes William A. Hawkins 67,405,961 1,128,994 6,744,219 John A. Bartholdson 68,365,980 168,975 6,744,219 Patrick J. Beyer 68,062,114 472,841 6,744,219 Robert E. Claypoole 68,360,467 174,488 6,744,219 Philip G. Cowdy 67,748,512 786,443 6,744,219 Ajay Dhankhar 68,459,149 75,806 6,744,219 Mary Kay Ladone 67,160,936 1,374,019 6,744,219 Michelle McMurry-Heath 68,073,685 461,270 6,744,219 Guido J. Neels 68,049,659 485,296 6,744,219 Guy P. Nohra 67,767,651 767,304 6,744,219 Susan M","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001665988-26-000035","anchor_url":"https://secwatch.observer/filing/0001665988-26-000035#claim-1b2b0369e0d046348c97cc511befab6d9fee084a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000035/0001665988-26-000035-index.htm"},{"fact_type":"earnings_release","fact_key":"3f38ebbc252b120765987fbaeba43a22e2abd456","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.04 per diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$3.1 million","period_text":"three months ended March 28, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$132.1 million"},"claim":"Bioventus Inc. reported three months ended March 28, 2026 results: revenue $132.1 million, net income $3.1 million, EPS $0.04 per diluted share. Guidance raised.","evidence_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001665988-26-000026","anchor_url":"https://secwatch.observer/filing/0001665988-26-000026#claim-3f38ebbc252b120765987fbaeba43a22e2abd456","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm"},{"fact_type":"debt_financing","fact_key":"0bd489c02952fe6fdef18be10ac86bccb4f3047f","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2025-08-04T23:59:59+00:00","payload":{"counterparty":"Wells Fargo Bank, National Association","effective_date":"2025-07-31","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"Term SOFR plus a margin of 2.50%","item_codes_triggered":["2.03"],"maturity_text":"July 31, 2030","principal_text":"a $100 million revolving credit facility and a $300 million first lien term loan A facility"},"claim":"Bioventus Inc. incurred credit facility of a $100 million revolving credit facility and a $300 million first lien term loan A facility with Wells Fargo Bank, National Association at Term SOFR plus a margin of 2.50% maturing July 31, 2030.","evidence_excerpt":"On July 31, 2025 (the “Closing Date”), Bioventus LLC, a Delaware limited liability company and subsidiary of Bioventus Inc. (“Bioventus LLC” or the “Company”) and certain of its subsidiaries entered into a Credit Agreement (the “2025 Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, and the lenders and other financial institutions party thereto. Pursuant to the 2025 Credit Agreement, the Company entered into a $100 million revolving credit facility (the “Revolving Credit Facility”) and a $300 million first lien term loan A facility (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-172192","anchor_url":"https://secwatch.observer/filing/0001193125-25-172192#claim-0bd489c02952fe6fdef18be10ac86bccb4f3047f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312525172192/0001193125-25-172192-index.htm"},{"fact_type":"earnings_release","fact_key":"816227e3b317eb35a64c9e768423b7cd9eb5a4c3","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.25 to $0.33","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2024","report_date":"2024-05-07","result_type":"guidance_update","revenue_text":"$535 million to $550 million"},"claim":"Bioventus Inc. reported full-year 2024 results: revenue $535 million to $550 million, EPS $0.25 to $0.33. Guidance raised.","evidence_excerpt":"Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects: • Net sales of $535 million to $550 million—An increase of $15 million from previous guidance • Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance • Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-020843","anchor_url":"https://secwatch.observer/filing/0001628280-24-020843#claim-816227e3b317eb35a64c9e768423b7cd9eb5a4c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm"},{"fact_type":"earnings_release","fact_key":"368a07c987813452c5b15c6bdb791fc0152f7c29","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"Loss per share of Class A common stock from continuing operations was $0.07","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss from continuing operations of $6.0 million","period_text":"three months ended March 30, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$129.5 million"},"claim":"Bioventus Inc. reported three months ended March 30, 2024 results: revenue $129.5 million, net income net loss from continuing operations of $6.0 million, EPS Loss per share of Class A common stock from continuing operations was $0.07.","evidence_excerpt":"For the first quarter, worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period. On an organic* basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions. The Company also reported a first quarter net loss from continuing operations of $6.0 million, compared to a net loss from continuing operations of $100.0 million in the prior-year period. Adjusted EBITDA* from continuing operations totaled $22.6 million, advancing 33.5%, compared to the prior year total of $17.0 million due to strong revenue growth and increased gross margin. Loss per share of Class A common stock from continuing operations was $0.07 in the first quarter, compared to a loss of $1.28 in the prior-year period.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-020843","anchor_url":"https://secwatch.observer/filing/0001628280-24-020843#claim-368a07c987813452c5b15c6bdb791fc0152f7c29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm"},{"fact_type":"earnings_release","fact_key":"4297151886f8eb5a728621001cf2c2c86dddf2dd","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":"$0.12 to $0.20","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2024","report_date":"2024-03-12","result_type":"guidance_update","revenue_text":"$520 million to $535 million"},"claim":"Bioventus Inc. reported Full Year 2024 results: revenue $520 million to $535 million, EPS $0.12 to $0.20. Guidance initiated.","evidence_excerpt":"Bioventus introduced its financial guidance for full-year 2024. The Company expects: • Net sales of $520 million to $535 million • Adjusted EBITDA* of $89 million to $94 million • Non-GAAP EPS* of $0.12 to $0.20","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-010371","anchor_url":"https://secwatch.observer/filing/0001628280-24-010371#claim-4297151886f8eb5a728621001cf2c2c86dddf2dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm"},{"fact_type":"earnings_release","fact_key":"b1296d3a70e99170ef630fcfc57faf13eab9225b","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":"($1.54) loss per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $121.2 million","period_text":"Full Year 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$512.3 million"},"claim":"Bioventus Inc. reported Full Year 2023 results: revenue $512.3 million, net income net loss of $121.2 million, EPS ($1.54) loss per share.","evidence_excerpt":"Bioventus’ full-year 2023 worldwide revenue totaled $512.3 million, which was even compared to the prior year. On an organic* basis, revenue increased 3.6%, driven by 9.4% growth in Surgical Solutions. The Company also reported a full-year 2023 net loss from continuing operations of $121.2 million, compared to net loss from continuing operations of $144.7 million in the prior year. Adjusted EBITDA from continuing operations* of $88.9 million advanced 29.5% from $68.6 million last year due to disciplined cost management and savings from a corporate restructuring implemented at the beginning of the year. Loss per share of Class A common stock from continuing operations was $1.54 per share, compared to a loss of $1.70 per share last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-010371","anchor_url":"https://secwatch.observer/filing/0001628280-24-010371#claim-b1296d3a70e99170ef630fcfc57faf13eab9225b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm"},{"fact_type":"earnings_release","fact_key":"163746068f3421f6002cc77a823d349c57618c94","cik":1665988,"ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":"($0.10) loss per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $7.7 million","period_text":"Fourth Quarter 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$135.4 million"},"claim":"Bioventus Inc. reported Fourth Quarter 2023 results: revenue $135.4 million, net income net loss of $7.7 million, EPS ($0.10) loss per share.","evidence_excerpt":"For the fourth quarter, worldwide revenue totaled $135.4 million, an increase of 7.6% compared to the prior year. On an organic* basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. The Company also reported a fourth quarter net loss from continuing operations of $7.7 million, compared to net loss from continuing operations of $35.4 million in the prior-year period. Adjusted EBITDA* from continuing operations of $22.0 million advanced 28.1% from $17.2 million last year due to strong revenue growth and disciplined cost management. Loss per share of Class A common stock from continuing operations was $0.10 per share, compared to a loss of $0.40 per share last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-010371","anchor_url":"https://secwatch.observer/filing/0001628280-24-010371#claim-163746068f3421f6002cc77a823d349c57618c94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm"}]}